Quantcast
Last updated on April 21, 2014 at 9:11 EDT

Cytocell Ltd Introduces New Haematology FISH Probes for Chronic Lymphocytic Leukaemia (CLL)

November 26, 2013

CAMBRIDGE, England, November 26, 2013 /PRNewswire/ –

Cytocell Ltd. announced the availability of a new range of in vitro diagnostic tests
to aid in detecting patients with Chronic Lymphocytic Leukaemia (CLL), a cancer of the
lymphocytes.

(Logo:
http://photos.prnewswire.com/prnh/20120906/559436 )

The new range of Cytocell CLL FISH probes includes the new CLL PROFILER Kit comprising
of the P53/ATM Probe Combination and a newly developed D13S319/13qter/12cen
Deletion/Enumeration probe. In total Cytocell has 19 different FISH probes specifically
designed with the intention of detecting abnormalities of the most common genes linked
with CLL.

CLL is the most common form of leukaemia in the U.S. and Europe and is most commonly
found in Caucasian men 60 years and older. In the United States, more than 15,000 patients
are diagnosed with CLL each year, many of whom are discovered during routine medical
exams. CLL progresses more slowly than other types of leukaemia and most patients
diagnosed with CLL have early-stage disease. Up to 50 percent are at risk for accelerated
progression while others live for many years and often do not require therapy.

Cytocell’s Aquarius(R) CLL PROFILER kit detects cytogenetic abnormalities in bone
marrow specimens and peripheral blood samples from patients with CLL. Deletions of ATM and
TP53 are the most serious rearrangements involved in CLL and detection of deletions of
these genes provides very important information as to the therapy choices for such
patients, especially since deletions of TP53 and ATM provide a poor prognosis.

“These new additions to our catalogue augments our already extensive collection of
FISH probes for leukaemia and provides comprehensive solution to the diagnosis of CLL,”
said Dr Martin Lawrie, Managing Director of Cytocell. “The launch of this product
demonstrates our continued focus on our range of Haematology probes which is continually
growing. We also believe that through our Custom FISH probe service, myProbes, we will be
able to offer more and more of such products for Haematology, driven by the clinical
requirements of our customers.”

About FISH

Chromosomal abnormalities have been shown to play a major role in disease evolution in
several haematological malignancies. Fluorescence In Situ Hybridisation (FISH), using
locus-specific probes, which are capable of defining numerical and structural chromosome
changes, has now become a routine diagnostic test in the clinical laboratory and the
technique has thus been shown to be useful in the management of cancer patients.

About Cytocell Ltd.

Cytocell is a leading European developer and manufacturer of FISH probes for use in
both routine cytogenetics and in the analysis and classification of Cancers. The Company’s
products are well established in Cytogenetics as the Company is celebrating its 20th year
of supplying them to this market. More recently, the Company has focused on developing
products for Oncology and now has a catalogue of some 350 products for Cytogenetics,
Haematology and Solid Tumour analysis as well as developing custom FISH probes for
customers with specific interests under the myProbes(R) brand. Cytocell’s products are
available through a well established distributor network, covering more than 60 countries
worldwide. Cytocell’s FISH probe service is currently proving to be invaluable to cancer
researchers and clinicians worldwide.

Cytocell’s news releases and other information are available on the company’s Web site
at http://www.cytocell.com.

For further enquiries, please contact:

        Stewart Kennedy,
        Sales & Marketing Director
        Tel: +44(0)7860-455527


    Photo: 

http://photos.prnewswire.com/prnh/20120906/559436

SOURCE Cytocell Ltd


Source: PR Newswire